Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Dr Raghunadharao Digumarti discusses his talk at the 1st Indian Cancer Congress about cancer as a heterogeneous disease, the plurality of cancer and how clinicians most combat the nature of cancer cells.
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
GIST tumours and soft tissue sarcomas
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
EAU 2024: Bladder cancer latest
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma